Struggling Arena Pharma axes 80 jobs, narrows R&D

Just a couple of weeks after booting company co-founder and CEO Jack Lief out of the company, a struggling Arena Pharmaceuticals ($ARNA) has followed up with a move to ax 35% of its staff--some 80 jobs--while narrowing its R&D focus. Arena has been losing market share with its obesity drug Belviq, which has proved to be a troublesome therapy to market. The focus at Arena now will be on "near-term" activities. Company shares are down 8% this morning. More cuts are also on the way. Release

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.